# XOMA Corporation (XOMA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/XOMA
## Company Profile
- Ticker: XOMA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 40.17 USD
- Market cap: 522835540.7 USD
- Last updated: 2026-07-13
## Business Overview
XOMA is a biotechnology company that has historically been known for antibody and royalty-based biotechnology assets. Its story is less about a single therapeutic program and more about portfolio management across biotech-related opportunities.
## Why The Stock Is Moving

Current closing-price context is not available for XOMA.

## Geographic Base

XOMA is headquartered in the United States and listed on NASDAQ. It sits in biotechnology with a portfolio and royalty orientation.

## Business Model

The company depends on asset selection, partnership value, and the ability to create returns from biotech-related rights and programs. Investors watch deal flow, royalties, and balance-sheet execution.

## Landscape Position

XOMA occupies a portfolio-style niche within biotech. It is different from a classic single-asset drug developer because value can come from multiple programs or royalty streams.

## Future Catalysts

- XOMA’s catalysts are royalty income, portfolio monetization, and any update that clarifies how the company is converting assets into value. The story is more about cash flow and capital allocation than pipeline risk.

## Recent News
- 2026-07-14 13:00 EST — [XOMA Royalty Announces Closing of Its Acquisition by Ligand](https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-closing-of-its-acquisition-by-ligand-6ca7a63d) — Source: XOMA Corporation
- 2026-06-12 20:05 EST — [XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date](https://biopharmsignal.com/news/XOMA/xoma-royalty-corporation-declares-quarterly-preferred-stock-dividend-and-announc-b8285e5a) — Source: XOMA Corporation
- 2026-04-27 11:00 EST — [Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator](https://biopharmsignal.com/news/XOMA/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator) — Source: XOMA Corporation
- 2026-03-18 20:30 EST — [XOMA Royalty Declares Quarterly Preferred Stock Dividends](https://biopharmsignal.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends) — Source: XOMA Corporation
- 2026-03-18 10:00 EST — [XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements](https://biopharmsignal.com/news/XOMA/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements) — Source: XOMA Corporation